http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
부산 일부 대학교 학생들의 니코틴 의존도와 구취의 연관성
김유린(외 5명) 신라대학교 자연과학연구소 2012 自然科學論文集 Vol.22 No.-
The purpose of this study is to examine the association of bad breath and nicotine dependency. By use of the findings from this study, This study conducted the survey of 53 smoker who visited dental hygiene lab for delivery from October to November 2012 with structured questionnaires(Fagerstrom Tolerance Questionnaire FTQ) and equipment(CO measuring instrument, Oral Chroma etc). The data were analyzed by using SPSS 20.0 program for χ2-test, ANOVA. Smokers' average age was 23 years old. The more higher nicotine dependence the more the average age was higher. The more higher nicotine dependence the less to nque brushing. No association of nicotine dependence and self-bad breath level. CO State was Significant differences(ND1(M=2.58), ND2(M=3.98), ND3(M=7.41), ND4(M=4.19), ND5(M=13.14))(F=2.616, p=.047). Dimethyl Sulfide was Significant differences(F=3.026, p=.026).
HBV : Postpartum Change of Clinical and Virologic Characteristic in Chronic Hepatitis B Patients
( Su Rin Shin ),( Hana Yoo ),( In Ho Moh ),( Ji Eun Song ),( Keun Young Lee ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: It has been known that a proportion of women with chronic hepatitis B experience hepatitis flare with or without HBeAg seroconversion following delivery. However, those results were based on retrospective data. This study aimed to evaluate postpartal change of clinical and virologic characteristics in Korean women with chronic hepatitis B prospectively. Methods: We conducted a prospective cohort of pregnant women with positive HBsAg identified in an antenatal screening program between 2010 to 2012. Aminotransferases, HBeAg status, and HBV DNA level were followed up every 4-week till 24 weeks after delivery. Results: Eighteen patients with mean age of 33 (20 to 40) were enrolled. Four patients had HBeAg-positive and DNA level over 107 copies/mL, and two of them were in immune tolerance phase. Of fourteen patients with HBeAg-negative, thirteen had HBV DNA level less than 104 copies/mL. Baseline ALT level at the time of delivery was 14 (7-123) U/mL and HBV DNA was 2.9 (1.5-8.2) log10 copies/mL. Change of median ALT level was +25, +16, +25, +17, +15, +13 U/L from the initial value at 4, 8, 12, 20, and 24 weeks after delivery. Median HBV DNA level decreased by -0.2 log10 copies/mL at week-4 but did not vary significantly through the study period. Change of median DNA level was -0.2, -0.9, -0.4, -0.9, -0.9, -1.0 log10 copies/mL at 4, 8, 12, 20, and 24 weeks after delivery. Exacerbation was noted in one patient who presented HBeAg positive and active hepatitis at the time of delivery. There was no HBeAg seroconversion. Conclusions: Our data indicated that significant reactivation of chronic hepatitis B is rare in postpartal period. However, the results of this study should be interpreted in that since the majority of patients enrolled had non-proliferative phase of hepatitis B.
Hepatitis C, LC : A case of spontaneous bacterial peritonitis by achromobacter xylosoxidans (초)
( Su Rin Shin ),( Myung Seok Lee ),( Eun Jeong Choi ),( Sang Hoon Park ),( Hyoung Su Kim ),( Myoung Kuk Jang ),( Ki Tae Suk ),( Dong Joon Kim ),( Ji Won Park ),( Choong Kee Park ) 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.3(S)
( Su Rin Shin ),( Sang Hoon Park ),( Myung Seok Lee ),( Jin Woo Lee ),( June Sung Lee ),( Young Seok Kim ),( Moon Seok Choi ),( Sook Hyang Jeong ),( Joo Hyun Shon ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Because of the limited geographic distribution of hepatitis C virus (HCV) genotype 6, there are insufficient data on its response to available treatment. This study was aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for genotype 6 chronic hepatitis C (CHC) patients in Korea. Methods: Data of 17 patients with genotype 6 CHC who were treated with peginterferon and ribavirin at 7 hospitals affiliated with Medical College in South Korea were reviewed. Results: There were 17 patients with genotype 6 (age 35-54 years, 41% male). Among them, data of 10 patients were from K(G)yeonggi-Incheon Peginterferon Alpha and Ribavirin Effect in CHC Treatment (KIPECT) study group. Subtypes were 6, 6a, 6a/c, and 6c in 1, 3, 1, and 12 patients, respectively. Baseline median alanine transaminase level was 82 (19-236) IU/mL, and HCV RNA level was 4,791,895 (356,089- 28,844,529 IU/mL). As follow-up loss occurred in 4 patients, a total of 13 patients conformed to the treatment protocol. Patients were treated with 180 μg of peginfeterfon alfa-2a or 1.5 μg/kg of peginterferon alfa-2b except one patient who were treated with 1.0 μg/kg of peginterferon alfa-2b with 800-1200 mg of ribavirin. Among 13 patients who followed the protocol, 6 patients attained sustained virologic response (SVR), 4 patients relapsed, 2 showed null-reponse, and 1 discontinued treatment with no early virologic response. Conclusions: Although there existed inconsistent regimens in treatment for patients with genotype 6 CHC, the SVR rate was observed as 46.1% (6/13). Considering that there has been no consensus in this issue, future studies should seek to clarify issues regarding prevalence, predictors for treatment response and the impact of ethnic and genotypic factors to treatment response in genotype 6 CHC patients.
( Su Rin Shin ),( Kwang Cheol Koh ),( Geum Youn Gwak ),( Moon Seok Choi ),( Joon Hyoek Lee ),( Seung Woon Paik ),( Byung Chul Yoo ) 대한소화기기능성질환·운동학회 2010 Gut and Liver Vol.4 No.4
Background/Aims: Adefovir (ADV) is the preferred drug for treating lamivudine (LAM)-resistant hepatitis B. However, not all patients who face virologic breakthrough during LAM treatment respond to ADV. The aim of this study was to determine the factors associated with efficacy of ADV in LAM-resistant hepatitis B patients. Methods: The medical records of 231 patients who received ADV due to LAM-resistance were reviewed. Efficacy was assessed by the initial virologic response (IVR), defined as hepatitis B virus (HBV) DNA not being undetectable by real-time PCR at 6 months of ADV treatment. Results: Seventy patients (30%) achieved IVR. While ``add-on`` modality, hepatitis B e antigen (HBeAg) negativity, and low baseline HBV DNA levels were associated with IVR in univariate analysis, multivariate analysis revealed HBeAg status and the DNA level to be the significant factors. The probability of IVR achievement increased sharply per each log10 copies/mL decrement in the baseline viral load, which was 133 times in patients who had HBV DNA <10(5) copies/mL compared with those who had ≥10(8) copies/mL. Conclusions: Factors associated with the IVR were HBeAg negativity and a low baseline viral load. Therefore, when virologic breakthrough with genotypic resistance emerges during LAM therapy, ADV treatment should be considered immediately before further increases in viral load. Additional long-term follow-up data are warranted. (Gut Liver 2010;4:530-536)
( Su Rin Shin ),( Sang Hoon Park ),( Myung Seok Lee ),( Jin Woo Lee ),( June Sung Lee ),( Young Seok Kim ),( Moon Seok Choi ),( Sook Hyang Jeong ),( Joo Hyun Shon ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Because of the limited geographic distribution of hepatitis C virus (HCV) genotype 6, there are insufficient data on its response to available treatment. This study was aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for genotype 6 chronic hepatitis C (CHC) patients in Korea. Methods: Data of 17 patients with genotype 6 CHC who were treated with peginterferon and ribavirin at 7 hospitals affiliated with Medical College in South Korea were reviewed. Results: There were 17 patients with genotype 6 (age 35-54 years, 41% male). Among them, data of 10 patients were from K(G)yeonggi-Incheon Peginterferon Alpha and Ribavirin Effect in CHC Treatment (KIPECT) study group. Subtypes were 6, 6a, 6a/c, and 6c in 1, 3, 1, and 12 patients, respectively. Baseline median alanine transaminase level was 82 (19-236) IU/mL, and HCV RNA level was 4,791,895 (356,089- 28,844,529 IU/mL). As follow-up loss occurred in 4 patients, a total of 13 patients conformed to the treatment protocol. Patients were treated with 180 μg of peginfeterfon alfa-2a or 1.5 μg/kg of peginterferon alfa-2b except one patient who were treated with 1.0 μg/kg of peginterferon alfa-2b with 800-1200 mg of ribavirin. Among 13 patients who followed the protocol, 6 patients attained sustained virologic response (SVR), 4 patients relapsed, 2 showed null-reponse, and 1 discontinued treatment with no early virologic response. Conclusions: Although there existed inconsistent regimens in treatment for patients with genotype 6 CHC, the SVR rate was observed as 46.1% (6/13). Considering that there has been no consensus in this issue, future studies should seek to clarify issues regarding prevalence, predictors for treatment response and the impact of ethnic and genotypic factors to treatment response in genotype 6 CHC patients.
Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma
( Su Rin Shin ),( Seung Woon Paik ),( Geum Youn Gwak ),( Moon Seok Choi ),( Joon Hyoek Lee ),( Kwang Cheol Koh ),( Byung Chul Yoo ) 대한소화기기능성질환·운동학회 2011 Gut and Liver Vol.5 No.1
Background/Aims: Despite great progress, antiviral treatment for chronic hepatitis C in patients with prior hepatocellular carcinoma (HCC) has been rarely investigated. We evaluated the effi cacy and safety of antiviral therapy following treatment for hepatitis C-related HCC. Methods: Thirteen patients (age 34 to 60 years) who were treated with peginterferon plus ribavirin after treatment for HCC were reviewed. Results: There were 6 patients with genotype 1 and 7 patients with genotype 2. All patients showed advanced fi brosis (≥F3) but belonged to the Child-Pugh class A. Treatment was stopped in 2 patients because of recurrent HCC and in 1 patient due to a lack of early virologic response. Seven patients achieved sustained virologic response and three patients relapsed. The sustained virologic response rate was 54% overall, 17% in genotype 1, and 86% in genotype 2. No signifi cant adverse events were reported. Conclusions: Antiviral therapy should not be excluded in patients who were previously treated with HCC with genotype 2 chronic hepatitis C, in which an effi cacious antiviral treatment for chronic hepatitis C was feasible. Additional study is needed to prove the validity of antiviral therapy in patients with genotype 1 hepatitis C-related HCC. (Gut Liver 2011;5:77-81)
( Su Rin Shin ),( Young Seok Kim ),( Young-seok Lim ),( June Sung Lee ),( Jin Woo Lee ),( Sun Myung Kim ),( Sook-hyang Jeong ),( Joo Hyun Sohn ),( Myung Seok Lee ),( Sang Hoon Park ) 대한간학회 2017 Gut and Liver Vol.11 No.2
Background/Aims: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea. Methods: From 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight hospitals. Results: Thirty-two patients had genotype 6 HCV. The median age was 44 years, and 6c was the most common subtype. The baseline median alanine transaminase level was 88 (21 to 1,019) IU/mL, and the HCV RNA level was 1,405,000 (96,500 to 28,844,529) IU/mL. Twenty-five patients were treated with peginterferon (PEG-IFN) and ribavirin. Three follow-up losses occurred. Additionally, 13 patients attained a sustained virologic response (SVR), seven patients relapsed, and two patients exhibited a null response. The SVR rates were 40% and 75% for the 24- and more than 48- week treatments, respectively, and five of the six patients who achieved a rapid virologic response (RVR) attained a SVR. Conclusions: Korean patients infected with genotype 6 HCV are relatively young, and 6c is the most common subtype. When treated with PEG-IFN and ribavirin, the SVR rate was 52%. Similar to other genotypes, a longer duration of treatment and attainment of RVR are important for SVR. (Gut Liver 2017;11:270-275)
모래지반에 설치된 병렬식 그룹석션앵커의 인발하중에 대한 수치해석 연구
김수린 ( Su Rin Kim ),추연욱 ( Yun Wook Choo ),권오순 ( O Soon Kwon ),김동수 ( Dong Soo Kim ) 한국현대언어학회 2014 언어연구 Vol.30 No.3
본 연구에서는 수치해석을 이용하여 모래지반에 설치된 병렬식 그룹석션앵커의 인발하중에 대한 거동을 분석하였다. 단일형과 병렬식 그룹석션 앵커에 대한 수치 모델을 구성하고 인발하중을 재하하여 하중재하점의 위치, 길이/직경비, 하중경사 및 단위앵커간 간격에 따른 그룹형 석션앵커의 인발지지력에 대한 영향을 연구하였다. 더블형과 트리플그룹앵커의 인발지지력은 단일앵커의 인발지지력 대비 1.7배와 2.4배로 나타났고, 설치간격이 증가함에 따라 그 증가율은 증가하였다. 하중재하점, 하중경사, 단위앵커의 형상비의 차이는 그룹앵커의 인발저항력 증가비에 큰 영향을주지 않는 것으로 나타났다. In this study, the performance of group suction anchors installed in sand and subjected to pullout loading was investigated by numerical analysis. The group suction anchors consist of two or three units rigidly connected to each other in parallel array and the pullout resistances were compared with that of a single anchor. Parametric study was performed using numerical models to study the effect of the physical conditions of the group anchor. The parameters include the skirt length to diameter ratio of a unit suction anchor, the pad-eye location, inclination of loading and the spacing between unit suction anchors. The analysis shows that the ratios of the pullout capacity of double suction anchor and triple suction anchor to that of single anchor are 1.7 and 2.4, respectively. The ratio increases with the increase in the spacing between the unit anchors. The other parameters such as the skirt length to the diameter ratio, the location of the pad-eye and the loading inclination have negligible effect on the ratio of pullout resistances of the group anchor to the single anchor.